Eli Lilly releases more data for new obesity drug, moving toward fast-track approval
There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.
In the summer of 2022, just as the hoopla surrounding the diabetes and weight loss drugs Ozempic and Wegovy was rising, doctors were surprised to see clinical trial results of a similar medication made by pharmaceutical giant Eli Lilly. Tirzepatide, marketed as Mounjaro for diabetes, showed even higher levels of weight loss: Participants had lost about 21% of their body weight, which was unprecedented.
The drug is already approved as an injectable prescription medicine for people with Type 2 diabetes. Now, the company
